Gsk Consumer Healthcare S.A. vs. Celebrity Biopharma Ltd. & Anr. (2024): A Landmark Decision on Pharmaceutical Trademark Similarity
| Particulars | Details |
|---|---|
| Court | Delhi High Court |
| Date Of Judgment | 22 March 2024 |
| Statute | Trade Marks Act, 1999 – Sections 57, 9, and 11 |
| Nature Of Case | Trademark Rectification / Cancellation |
Introduction
Trademark law performs a dual function. It protects the commercial goodwill of businesses while simultaneously safeguarding consumers from confusion in the marketplace. These objectives assume heightened importance in the pharmaceutical sector, where confusion between two similar medicines can potentially endanger public health.
The decision of the Delhi High Court in GSK Consumer Healthcare S.A. v. Celebrity Biopharma Ltd. & Anr. (2024) illustrates how Indian courts apply the principles of deceptive similarity and prior user rights in pharmaceutical trademarks.
The Court examined whether the mark “OTRINIR” could coexist with the well-known nasal decongestant brand “OTRIVIN”, and ultimately ordered cancellation of the later mark from the trademark register.
The judgment reinforces the judiciary’s consistent approach that even minor similarities between pharmaceutical trademarks may be unacceptable, particularly where the earlier mark enjoys longstanding reputation.
1. Background Of The Dispute
The petitioner, GSK Consumer Healthcare S.A., forms part of the global GlaxoSmithKline group, a multinational pharmaceutical and healthcare corporation. The company owns the trademark “OTRIVIN”, widely used for nasal decongestant sprays.
The OTRIVIN brand has existed in the market since around 1950, and over decades it has acquired substantial reputation and goodwill among doctors, pharmacists, and consumers.
The dispute arose when Celebrity Biopharma Ltd., the respondent, obtained registration of the mark “OTRINIR” in Class 5 under the Trade Marks Act, covering pharmaceutical preparations, including nasal sprays.
Timeline Of Events
| Year / Date | Event |
|---|---|
| 1950s | OTRIVIN introduced internationally as a nasal decongestant. |
| Subsequent decades | Extensive sales and reputation established. |
| 2013 | Celebrity Biopharma adopts and registers OTRINIR. |
| April 2020 | GSK becomes aware of the registration. |
| 1 August 2020 | GSK sends a legal notice demanding cessation of use. |
| Respondent refuses | Leading to litigation. |
| Rectification petition filed | Filed under Section 57 of the Trade Marks Act before the Delhi High Court. |
| 22 March 2024 | Court delivers judgment. |
2. Legal Framework
The dispute involved key provisions of the Trade Marks Act, 1999.
Section 57 – Rectification And Cancellation
Section 57 allows any aggrieved person to apply for removal or cancellation of a trademark from the register if the registration:
- was wrongly made; or
- remains wrongly on the register.
Rectification petitions are often used when a mark is registered despite conflicting with an earlier trademark.
Section 9 – Absolute Grounds For Refusal
Section 9 prohibits registration of marks that are likely to deceive or cause confusion.
Section 11 – Relative Grounds For Refusal
Section 11 bars registration of a trademark if:
- it is identical or similar to an earlier mark, and
- the goods/services are identical or similar, creating a likelihood of confusion.
Together, these provisions ensure that later trademarks do not encroach upon established brand rights.
| Provision | Purpose Under The Trade Marks Act, 1999 |
|---|---|
| Section 57 | Allows rectification or cancellation of wrongly registered trademarks. |
| Section 9 | Prevents registration of deceptive or confusing trademarks. |
| Section 11 | Protects earlier trademarks against similar later registrations. |
3. Central Legal Issue
The principal question before the Court was:
Whether the trademark “OTRINIR” is deceptively similar to GSK’s earlier mark “OTRIVIN”, thereby creating a likelihood of confusion among consumers purchasing pharmaceutical products.
The Court had to evaluate similarity from multiple perspectives, including:
- phonetic similarity
- visual resemblance
- structural composition
- nature of goods
- likelihood of confusion in the pharmaceutical market
4. Arguments Presented By GSK (Petitioner)
GSK advanced several arguments to demonstrate that the impugned mark should be cancelled.
(a) Prior Use And Global Reputation
The company argued that OTRIVIN is a long-established pharmaceutical brand with global recognition.
Decades of continuous use, extensive advertising, and significant sales had given the mark substantial goodwill in India and internationally.
Under trademark law, the prior user principle ensures that earlier commercial use prevails over later adoption.
(b) Deceptive Similarity
According to GSK:
- Both marks begin with “OTRI”, the dominant portion.
- Consumers are likely to focus on the prefix rather than the suffix.
- When spoken, OTRIVIN and OTRINIR sound highly similar.
This similarity was argued to create a real risk of consumer confusion, particularly in fast-paced retail environments such as pharmacies.
(c) Identical Goods
Both marks were used for nasal decongestant sprays, falling within the same pharmaceutical category.
Where goods are identical, courts apply a stricter test of similarity, because confusion becomes more likely.
(d) Dishonest Adoption
GSK suggested that the respondent’s choice of the mark was not coincidental.
Given the long-standing presence of OTRIVIN in the pharmaceutical market, the respondent likely adopted OTRINIR to benefit from the reputation of the earlier brand.
(e) Violation Of Statutory Provisions
GSK argued that the impugned registration violated:
- Section 9(2)(a) – likelihood of deception
- Section 11 – conflict with earlier trademark rights
Therefore, the registration should be removed from the trademark register.
5. Respondent’s Arguments
Celebrity Biopharma resisted the rectification petition and raised several defenses.
(a) “OTRI” Is Generic
The respondent claimed that the prefix “OTRI” is derived from otorhinolaryngology (ENT) and is therefore common in pharmaceutical nomenclature.
If the prefix were considered generic or descriptive, it could not be monopolized by GSK.
(b) Distinct Suffix
Celebrity Biopharma argued that the suffix “NIR” sufficiently distinguishes the mark from “VIN”.
Thus, the marks OTRINIR and OTRIVIN should be considered distinct.
(c) Anti-Dissection Rule
The respondent relied on the anti-dissection principle, which states that trademarks must be evaluated as a whole, rather than dissected into individual components.
In support, reliance was placed on the landmark Supreme Court decision in:
- Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd. (2001)
In that case, the Court held that similarity must be judged from the perspective of an average consumer with imperfect recollection.
6. The Court’s Analysis
The Delhi High Court undertook a detailed comparison of the competing marks.
(1) Phonetic Similarity
Both marks begin with “OTRI”, and when pronounced, the overall sound of OTRIVIN and OTRINIR is strikingly similar.
Phonetic similarity carries particular importance in pharmaceutical products because:
- medicines are often ordered verbally, and
- prescriptions may be spoken or handwritten.
(2) Structural Similarity
The Court noted that:
- both marks consist of seven letters, and
- share the same initial structure.
This structural resemblance increases the likelihood of confusion.
(3) Visual Similarity
Visually, the marks appear closely related.
The shared prefix OTRI creates a dominant impression that overshadows the differing suffix.
(4) Nature Of Goods
Both marks relate to nasal decongestant sprays.
Where goods are identical, even small differences between marks may not prevent confusion.
(5) Prior Use And Reputation
The Court placed significant weight on GSK’s long-standing use of OTRIVIN.
The respondent’s adoption in 2013 came decades after the establishment of the earlier brand.
(6) Generic Argument Rejected
The Court rejected the respondent’s claim that “OTRI” was generic.
The respondent failed to produce sufficient evidence of widespread use of the prefix in the pharmaceutical trade.
Therefore, the Court held that the prefix retained distinctive association with OTRIVIN.
7. The Judgment
The Delhi High Court ultimately ruled in favour of GSK.
Key Findings
The Court held that:
- OTRINIR is deceptively similar to OTRIVIN
- The mark was registered in violation of Sections 9 and 11 of the Trade Marks Act
- The respondent’s mark could not coexist with the earlier well-known brand.
Court’s Directions
The Court ordered:
- Cancellation of the trademark “OTRINIR” (Application No. 2892712)
- Removal of the mark from the Trademark Register
- The Trademark Registry to update its records accordingly.
8. Legal Principles Reinforced by the Judgment
This decision strengthens several important doctrines in trademark law.
1. Prior User Prevails
Indian trademark law gives greater importance to prior use than registration.
- Even a registered mark can be cancelled if it conflicts with an earlier user.
2. Deceptive Similarity Test
Courts assess similarity based on:
- Phonetic resemblance
- Visual appearance
- Structural composition
- Nature of goods
- Consumer perception
3. Higher Standard for Pharmaceutical Trademarks
Courts apply stricter scrutiny in pharmaceutical cases.
Even minor confusion between drug names can result in:
- Dispensing of the wrong medicine
- Potential health risks.
This principle was strongly emphasized in the Supreme Court decision Cadila Health Care v. Cadila Pharmaceuticals (2001).
4. Prefix Dominance Rule
Consumers often remember the beginning of a word mark.
- Therefore, identical prefixes can create strong consumer association.
5. Public Interest in Trademark Law
Trademark disputes are not merely commercial conflicts.
- In pharmaceutical cases, they involve public health considerations.
9. Practical Lessons for Businesses and Lawyers
The decision offers several practical insights.
For Pharmaceutical Companies
- Conduct thorough trademark searches before adopting a brand name.
- Avoid names resembling well-known drug brands.
- Ensure brand names are distinctive and original.
For Trademark Lawyers
Gather extensive evidence of prior use, including:
- Sales figures
- Advertising expenditure
- Market reputation
Emphasize public health implications in pharmaceutical disputes.
For Trademark Registry
The judgment underscores the importance of careful examination during trademark registration, particularly in Class 5 pharmaceutical marks.
10. Broader Impact of the Decision
The ruling contributes to a growing body of Indian jurisprudence emphasizing strict protection for pharmaceutical trademarks.
It signals that courts will not permit free-riding on established brands, particularly where such conduct may mislead consumers.
The decision also reinforces the importance of distinctive brand creation in the pharmaceutical industry, encouraging companies to adopt inventive and unique names rather than derivative ones.
Conclusion
The Delhi High Court’s decision in GSK Consumer Healthcare S.A. v. Celebrity Biopharma Ltd. (2024) is a significant reaffirmation of core trademark principles under Indian law.
By cancelling the mark OTRINIR, the Court emphasized that:
- Long-standing pharmaceutical brands deserve strong legal protection, and
- Consumer safety must remain paramount in trademark disputes involving medicines.
Ultimately, the ruling reiterates a fundamental principle of trademark jurisprudence:
Where confusion in the pharmaceutical market is possible, the law must err on the side of caution.
The judgment serves as a clear reminder that distinctiveness and diligence in brand selection are essential in the healthcare sector.
Take Action: Protect Your Copyright the Right Way
Copyright registration may not be permanent or untouchable, but a properly prepared and legally sound registration can become a powerful shield for your intellectual property. The difference often lies in how the registration is filed, the documentation provided, and the legal strategy behind the application.
Many copyright registrations face challenges later because of:
- Incorrect ownership details
- Missing agreements or assignments
- Poor description of the work
- Lack of supporting documentation
- Applications filed without proper legal guidance
Such mistakes can make even a registered copyright vulnerable to cancellation or rectification by the court.
If you truly want your copyright to stand strong against legal challenges, it is essential that the registration is filed correctly from the very beginning.
Legal Service India.com, one of India’s pioneering independent legal knowledge platforms founded in August 2000, provides professional copyright registration assistance through experienced intellectual property lawyers. Our team ensures that your copyright application is accurate, properly documented, and legally structured to withstand future disputes.
Whether you are:
- An author or publisher
- A software developer or startup
- A designer or creative professional
- A business protecting logos, content, or digital assets
we help ensure that your copyright registration is legally robust, defensible, and difficult to challenge.
️ Do not leave your intellectual property vulnerable to disputes.
Secure your copyright the right way with expert legal guidance.
👉 Contact Legal Service India.com today for professional Copyright Registration assistance and make your copyright legally strong and dispute-resistant.
🌐 Website: File Copyright Registration
📱 WhatsApp: +91 9891244487
Protect your creativity. Secure your rights. Strengthen your copyright.
